Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298350 · ClinicalTrials.gov registry record · Phase 2
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 278
- Enrollment target
NCT00298350 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 278 participants.
The verdict
NCT00298350, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 278 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have failed, or are failing, protease inhibitor therapy.
Interventions
- DRUG GS-9137 - A Novel HIV-1 Integrase Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00298350
The ClinicalTrials.gov registry entry for NCT00298350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GS-9137 - A Novel HIV-1 Integrase Inhibitor is the first listed.
NCT00298350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00298350 about?
NCT00298350 is a clinical study titled "Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.". The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have failed, or are failing, protease inhibitor therapy.
What is the current status of trial NCT00298350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2006-02. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00298350?
The interventions under investigation include: GS-9137 - A Novel HIV-1 Integrase Inhibitor (DRUG).
Who is sponsoring clinical trial NCT00298350?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.